ASP‐1929, a pivotal antibody‐drug conjugate within Rakuten Medical's pipeline, shows promise in its capacity to bind with EGFR prevalent in various solid tumors.[136] Upon activation by NIR light, ASP‐1929 triggers a biophysical cascade that ultimately leads to cell death and degradation of tumor tissue.[137] With conditional early approval from the Japanese Ministry of Health, Labor, and Welfare, ASP‐1929 is in the midst of a global phase III clinical trial for recurrent head and neck cancer. Here, EGFR is linked to neoplasm.